Celecoxib inhibits β-catenin-dependent survival of the human osteosarcoma MG-63 cell line

Journal of International Medical Research

Volumn 38, Issue 4, 2010, Pages 1294-1304

  Xia, J J ^a   Pei, L B ^a   Zhuang, J P ^a   Ji, Y ^a   Xu, G P ^a   Zhang, Z P ^a   Li, N ^a   Yan, J L ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Celecoxib; Glycogen synthase kinase (GSK) 3 ; MG 63 cell line; Osteosarcoma; RNA interference (RNAI); catenin

Indexed keywords

BETA CATENIN; CELECOXIB; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; MYC PROTEIN;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION TERMINATION;

EID: 77957734800     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800411     Document Type: Article

References (33)

1. Cotterill SJ, Wright CM, Pearce MS, et al: Stature of young people with malignant bone tumors. Pediatr Blood Cancer 2004; 42: 59-63.
2. Fagioli F, Biasin E, Mereuta OM, et al: Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transplant 2008; 41(suppl 2): S131-S134.
3. Maier TJ, Janssen A, Schmidt R, et al: Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005; 19: 1353-1355.
4. Takemaru KI, Ohmitsu M, Li FQ: An oncogenic hub: β-catenin as a molecular target for cancer therapeutics. Handb Exp Pharmacol 2008; 186: 261-284.
5. Zhang H, Xue Y: Wnt pathway is involved in advanced gastric carcinoma. Hepatogastroenterology 2008; 55: 1126-1130.
6. Conacci-Sorrell ME, Ben-Yedidia T, Shtutman M: Nr-CAM is a target gene of the β-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 2002; 16: 2058-2072.
7. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al: The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 1999; 18: 2883-2891.
8. He TC, Sparks, AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
9. Tetsu O, McCormick F: β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
10. Sabino MA, Ghilardi JR, Jongen JL, et al: Simultaneous reduction in cancer pain, bone destruction and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002; 62: 7343-7449.
11. Liu B, Shi ZL, Feng J, et al: Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int 2008; 32: 494-501.
12. Haydon RC, Deyrup A, Ishikawa A, et al: Cytoplasmic and/or nuclear accumulation of the β-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002; 102: 338-342.
13. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
14. Koki AT, Masferrer JL: Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002; 9(2 suppl): 28-35.
15. Arun B, Goss P: The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004; 31(2 suppl 7): 22-29.
16. Cho SJ, Kim N, Kim JS, et al: The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig Dis Sci 2007; 52: 1713-1721.
17. Soh JW, Kazi JU, Li H, et al: Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog 2008; 47: 519-525.
18. Amir M, Agarwal HK: Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie 2005; 60: 563-570.
19. Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 2002; 94: 252-266.
20. Cui W, Hu SX, Tang ZY, et al: In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. Anticancer Drugs 2008; 19: 891-897.
21. Boon EM, Keller JJ, Wormhoudt TA, et al: Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 2004; 90: 224-229.
22. Buchanan FG, DuBois RN: Connecting COX-2 and Wnt in cancer. Cancer Cell 2006; 9: 6-8.
23. Kim SH, Song SH, Kim SG, et al: Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target. J Cancer Res Clin Oncol 2004; 130: 551-560.
24. Zhang H, Ye Y, Bai Z, et al: The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway. Dig Dis Sci 2008; 53: 2195-2203.
25. MacDonald BT, Tamai K, He X: Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.
26. Reinhardt J, Ferandin Y, Laurent M: Purification of CK1 by affinity chromatography on immobilised axin. Protein Expr Purif 2007; 54: 101-109.
27. Hart M, Concordet JP, Lassot I, et al: The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell. Curr Biol 1999; 9: 207-210.
28. Berx G, Nollet F, Roy FV: Dysregulation of the Ecadherin/catenin complex by irreversible mutations in human carcinomas. Cell Adhes Commun 1998; 6: 171-184.
29. Malbon CC: β-Catenin, cancer, and G proteins: not just for frizzleds anymore. Sci STKE 2005; 292: pe35.
30. Polakis P, Hart M, Rubinfeld B: Defects in the regulation of beta-catenin in colorectal cancer. Adv Exp Med Biol 1999; 470: 23-32.
31. Goto H, Kawano K, Kobayashib I, et al: Expression of cyclin D1 and GSK-3β and their predictive value of prognosis in squamous cell carcinomas of the tongue. Oral Oncol 2002; 38: 549-556.
32. Soda M, Willert K, Ernst B, et al: Inhibition of GSK-3β promotes survival and proliferation of megakaryocytic cells through a β-cateninindependent pathway. Cell Signal 2008; 20: 2317-2323.
33. Mulholland DJ, Dedhar S, Wu H, et al: PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer. Oncogene 2006; 25: 329-337.